AUTHORS
Wu Shishuang, MD, Jun Zhu2, Bo Lv3, Jiayi Ren4, Fengxuan Zhang5, Yuting Tao6, Kai Qing7, Kai Xue, MD8
AFFILIATIONS
1 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Shanghai Liquan Hospital, Shanghai, China
3 Shanghai Liquan Hospital, Shanghai, China
4 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 The First School of Clinical Medicine, Nanjing Medical University, Nanjing, China
6 Shanghai Liquan Hospital, Shanghai, China
7 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
8 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
ABSTRACT
Background: Lymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) carries a grave prognosis, with mortality exceeding 50% under etoposide-based regimens. Many patients are ineligible for cytotoxic chemotherapy due to severe multi-organ dysfunction at presentation. The ruxolitinib-dexamethasone (Ru-D) backbone achieved a 2-month overall response rate [ORR] of 85.7% in newly diagnosed HLH (Zhou et al, Blood 2025), though its lymphoma-associated subgroup exhibited poor outcomes. Whether a chemotherapy-free anti-inflammatory regimen can achieve meaningful disease control as a bridge to lymphoma-directed therapy remains unknown.
Methods: We evaluated VC+Ru+D (dexamethasone 10 mg/m²/day, ruxolitinib 10 mg twice daily, and intravenous vitamin C 200 mg/kg/day) as initial therapy in 34 consecutive LA-HLH patients (median age 54.5 years, range 15–74; 74% male) at Ruijin Hospital, Shanghai (2024–2026). Lymphoma subtypes comprised B-cell (n=20, predominantly ) and T/NK-cell lineages (n=14, including extranodal NK/T-cell lymphoma, angioimmunoblastic T-cell lymphoma, and peripheral T-cell lymphoma not otherwise specified)). EBV co-infection was present in 11 patients (32%). Primary endpoint: day-28 ORR, defined as the percentage of patients with complete response (CR), partial response (PR), or improvement in HLH measures, consistent with Zhou et al. Secondary endpoints: paired D0–D4 laboratory changes (Wilcoxon signed-rank test; nominal two-sided P values, unadjusted for multiplicity), mortality, and adverse events graded by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
Results: Paired D0/D4 data were available for all 34 patients. Total bilirubin improved significantly (26.3→18.1 µmol/L, −30.9%, P=0.003). Hemoglobin decreased (79.5→67.5 g/L, −15.1%, P=0.011). Other parameters including platelet count, alanine aminotransferase, aspartate aminotransferase, ferritin, soluble CD25, white blood cell count, triglycerides, and fibrinogen remained stable. At day 28, 27 patients achieved partial response (ORR 79.4%); two patients who died before assessment were counted as non-responders. No patient achieved complete response, consistent with the anti-inflammatory regimen that controls the cytokine storm without eradicating the underlying lymphoma; residual lymphoma sustains HLH activity, so durable complete remission requires subsequent lymphoma-directed therapy. As a bridge, 14 patients (41.2%) proceeded to hematopoietic stem cell transplantation. With a median follow-up of 10.4 months (range 3.9–19.9), ten deaths occurred (29.4%), all in patients with advanced-stage lymphoma and multi-organ failure at treatment initiation: three within 28 days of treatment initiation; five after day 28 in patients not bridged to transplantation; and two during transplantation. The safety profile was dominated by cytopenias (anemia 97%, leukopenia 90%, thrombocytopenia 90%) and infection (77%, grade ≥3 in 61%), consistent with severe baseline bone marrow compromise from underlying lymphoma. Hemorrhage (6%) and pancreatitis (3%) were rare. No unexpected toxicities attributable to the regimen were observed.
Conclusions: VC+Ru+D as initial anti-inflammatory therapy achieved a 79.4% day-28 ORR in a cohort with predominantly advanced-stage lymphoma, supporting the feasibility of a chemo-free bridge strategy in LA-HLH. Complete responses were not expected without lymphoma-directed treatment, yet rapid inflammatory control enabled bridging to definitive therapy. The toxicity profile, dominated by hematologic events consistent with underlying disease severity, supports prospective evaluation of this regimen as a platform for bridging to definitive lymphoma treatment.
DISCLOSURES
Wu Shishuang, MD: No relevant conflicts of interest to declare.